Home » Blog » S-Ruxolitinib: a novel JAK/STAT-targeted therapy through restoring mucosal homeostasis for chronic rhinosinusitis with nasal polyps
S-Ruxolitinib: a novel JAK/STAT-targeted therapy through restoring mucosal homeostasis for chronic rhinosinusitis with nasal polyps
0 Views
SaveSavedRemoved 0
S-Ruxolitinib, a novel JAK/STAT inhibitor, successfully reduces sinonasal irritation and restores mucosal homeostasis in power rhinosinusitis with nasal polyps, providing a promising new therapeutic choice.
Trending Merchandise
Added to wishlistRemoved from wishlist 0
$25.00
Added to wishlistRemoved from wishlist 0
$29.71
Added to wishlistRemoved from wishlist 0
$32.99
Added to wishlistRemoved from wishlist 0
$13.99
Added to wishlistRemoved from wishlist 0
$17.99
Added to wishlistRemoved from wishlist 0
$7.85
Added to wishlistRemoved from wishlist 0
$8.83
Added to wishlistRemoved from wishlist 0
$45.40
Added to wishlistRemoved from wishlist 0
$9.99
Carlyle Cat’s Claw Capsules 1000mg | 180 Count | Uncaria Tomentosa | Non-GMO, Gluten Free Supplement
Added to wishlistRemoved from wishlist 0
$15.28